《大行》花旗:药明生物(02269.HK)售爱尔兰疫苗设施 对财务无负面影响并将改善整体盈利能力

阿斯达克财经
07 Jan

药明生物(02269.HK) 较早前公布,向默沙东(MSD International)出售与爱尔兰疫苗设施相关的资产,总对价约5亿美元(约39亿港元)。
花旗发表研报指,虽然药明生物剥离指定海外设施的举措合符市场预期,但仍有部分人或将出售资产视为针对潜在地缘政治风险的防御行动。该行认为,上述爱尔兰疫苗设施交易不会对该公司产生负面财务影响,并将改善其整体获利能力。

花旗予药明生物目标价为30元,给予“买入”。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10